Outcomes of radiosensitisation in elderly patients with advanced bladder cancer.
Authors
Christodoulou, MariannaReeves, K
Hodgson, Clare
Zeniou, A
Slevin, F
Kennedy, J
Hoskin, P
Henry, A
Choudhury, Ananya
Affiliation
Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, United KingdomIssue Date
2018-06-02
Metadata
Show full item recordAbstract
There is little evidence to guide treatment in elderly patients with muscle invasive bladder cancer (MIBC). We evaluated the efficacy and tolerability of concurrent radical radiotherapy with gemcitabine radiosensitisation (GemX) in elderly patients with MIBC and compared outcomes to those from the bladder carbogen and nicotinamide (BCON) phase III trial.Citation
Outcomes of radiosensitisation in elderly patients with advanced bladder cancer. 2018, Radiother OncolJournal
Radiotherapy and OncologyDOI
10.1016/j.radonc.2018.05.022PubMed ID
29871812Type
ArticleLanguage
enISSN
1879-0887ae974a485f413a2113503eed53cd6c53
10.1016/j.radonc.2018.05.022
Scopus Count
Collections
Related articles
- Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer.
- Authors: Thompson C, Joseph N, Sanderson B, Logue J, Wylie J, Elliott T, Lyons J, Anandadas C, Choudhury A
- Issue date: 2017 Mar 15
- Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
- Authors: Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, Symonds P, Wylie JP, Ramani V, Sangar V, Lyons J, Bottomley I, McCaul D, Clarke NW, Kiltie AE, Cowan RA
- Issue date: 2011 Feb 20
- Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?
- Authors: Hurmuz P, Ozyigit G, Kilickap S, Esen CSB, Akdogan B, Ozen H, Akyol F
- Issue date: 2021 Jun
- Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399).
- Authors: Song YP, Mistry H, Irlam J, Valentine H, Yang L, Lane B, West C, Choudhury A, Hoskin PJ
- Issue date: 2021 Aug 1
- Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer.
- Authors: Caffo O, Fellin G, Graffer U, Valduga F, Bolner A, Luciani L, Tomio L, Galligioni E
- Issue date: 2003 Dec 1